Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension (NCT02543658) | Clinical Trial Compass
CompletedPhase 2
Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
China80 participantsStarted 2015-09-01
Plain-language summary
Acute pancreatitis(A) often complicated with Intra-abdominal Hypertension. After the onset of acute pancreatitis, capillary leakage causing ascites,upper gastrointestinal tract obstruction and paralytic ileus leading to an elevated IAP, severe IAH leads to ACS with high mortality. Neostigmine is an anti-cholinesterase drugs, can enhance intestinal peristalsis, promote flatus defecation. The aim of this study was to determine the effect of neostigmine on reducing abdominal pressure and clinical prognosis in patients with AP by promoting intestinal peristalsis and defecation.
Who can participate
Age range18 Years ā 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age 18-70 year ;
ā. The diagnosis of acute pancreatitis according to the revised Atlanta classification.
ā. IAH is defined as IAP ā„ 12 mmHg by the World Society of Abdominal;Compartment Syndrome (WSACS);
ā. After 24 hours of conventional treatment(such as gastrointestinal decompression or percutaneous drainage of ascites), the IAP of AP patients with IAH was still ā„ 12 mmHg;
ā. The onset time of acute pancreatitis was within 2 weeks;
ā. Signed the informed consent.
Exclusion criteria
ā. Previous history of laparotomy;
ā. Mechanical ileus or abdominal hemorrhage were considered clinically;
ā. Those who have contraindications to neostigmine: 1) Patients with angina; 2) myocardial infarction; 3) ventricular tachycardia; 4) bradycardia; 5) acute circulatory failure; 6) epilepsy; 7) bronchial asthma; 8) mechanical intestinal obstruction; 9) urinary tract infarction; 10) hyperthyroidism; 11) serious arrhythmia; 12) bladder operation; 13) intestinal fistula;
What they're measuring
1
Percent Change of IAP After Treatment
Timeframe: From randomization to 7 days after treatment,Measured IAP every 6 hours
Trial details
NCT IDNCT02543658
SponsorThe First Affiliated Hospital of Nanchang University